
1. Cancer Cell. 2021 Nov 8;39(11):1448-1449. doi: 10.1016/j.ccell.2021.10.002. Epub 
2021 Oct 12.

Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional TÂ cell
response in allogeneic stem cell transplantation recipients.

Harrington P(1), Doores KJ(2), Saha C(3), Saunders J(3), Child F(3), Dillon R(4),
Saglam S(3), Raj K(3), McLornan D(3), Avenoso D(5), Kordasti S(1), O'Reilly A(3),
Espehana A(3), Lechmere T(2), Khan H(2), Malim MH(2), Harrison C(1), Mehra V(5), 
de Lavallade H(6).

Author information: 
(1)Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, 
London, UK; School of Cancer and Pharmaceutical Science, King's College London,
London, UK.
(2)Department of Infectious Diseases, School of Immunology & Microbial Sciences, 
King's College London, London, UK.
(3)Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, 
London, UK.
(4)Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, 
London, UK; Department of Medicine & Molecular Genetics, King's College London,
London, UK.
(5)Department of Haematological Medicine, King's College Hospital, London, UK.
(6)Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, 
London, UK; School of Cancer and Pharmaceutical Science, King's College London,
London, UK. Electronic address: h.delavallade@nhs.net.

DOI: 10.1016/j.ccell.2021.10.002 
PMCID: PMC8506143
PMID: 34717827  [Indexed for MEDLINE]

Conflict of interest statement: Declaration of interests P.H. received research
funding from Bristol Myers Squibb and speaker fees from Incyte. D.M. received
speaker fees and advisory boards Novartis, Celgene, and Jazz pharmaceuticals.
S.K. received Celgene and Novartis research grant and Alexion speaker honorarium.
C.H. received speaker fees from Novartis, Jannsen, CTI, Celgene, and Medscape and
has served on the advisory board for Incyte, CTI, Sierra Oncology, Novartis,
Celgene, Roche, AOP Pharma, Geron, and Astra Zenica. H.d.L. has received grants
and speakers fees from Bristol Myers Squibb and Incyte and speaker fees from
Novartis.

